Wanbury Launches Commercial Production of Key Anaesthetic API, Targets Incremental Rs.100 Crore Revenue in FY 2026-27

Wanbury Limited, a leading pharmaceutical company, has announced the commencement of commercial production for a high-potent anaesthetic API at its state-of-the-art facility in Tanuku, Andhra Pradesh. This milestone is expected to generate incremental revenues of approximately Rs. 18 crore in Q4 FY 2025-26. The upcoming multi-purpose intermediate production block at Tanuku is on track for commercial readiness by the end of March 2026, which will enable the production of four additional high-value APIs: Antidiabetic, Anticoagulant (Blood thinner), Cough suppressant (Anti Tussive), Antidepressant. These four molecules are projected to deliver over Rs. 100 crore in revenues for Wanbury in FY 2026-27. The worldwide market for these new APIs is currently valued at over Rs. 5,000 crore, presenting substantial growth opportunities.